San Diego-based Adventrx Pharmaceuticals announced that it presented positive efficacy and safety data from its Phase II multi-center CoFactor clinical trial at the 2006 Gastrointestinal Cancers Symposium in San Francisco. Objective results from an independent radiology organization concluded there was an overall clinical benefit of 85 percent.
- read this release for more information